准PCK1以克服CDK4/6抑制剂的耐药性,用于乳腺癌治疗
Chen-Shiou Wu1, Hsiao-Fan Chen2, Kieu-Thanh Huynh3
1Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan; Cancer Biology and Precision Therapeutics Center and Research Center for Cancer Biology, China Medical University, Taichung, Taiwan; Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan.
Cancer letters
|February 26, 2026
概括
基酸碳素激酶1 (PCK1) 促进乳腺癌的生长和对CDK4/6抑制剂的抵抗. 向PCK1使用everolimus或auranofin与CDK4/6抑制剂协同作用,提供了新的乳腺癌治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 基酸碳酸酶1 (PCK1) 在癌症中具有双重作用,在某些癌症中充当瘤基因,在其他癌症中充当瘤抑制剂.
- 了解PCK1在不同癌症类型中的特定作用对于开发有效的向疗法至关重要.
研究的目的:
- 研究PCK1在乳腺癌恶性瘤中的作用.
- 阐明PCK1对瘤发生和治疗耐药性的机制.
- 确定针对乳腺癌中PCK1的潜在治疗策略.
主要方法:
- 利用乳腺癌模型研究PCK1的功能.
- 研究了PCK1与Cyclin D3和CDK4/6.6的相互作用.
- 进行药物查以确定PCK1抑制剂.
- 在乳腺癌模型中评估PCK1抑制剂和CDK4/6抑制剂的协同作用.
主要成果:
- 在乳腺癌中,PCK1促进细胞增殖,殖民地形成和DNA合成.
- PCK1与Cyclin D3相互作用,在临床样本中具有积极的相关性.
- PCK1被确定为CDK4/6抑制剂耐药性的关键因素.
- 埃弗罗利慕斯和奥拉诺芬被确定为PCK1抑制剂,显示与CDK4/6抑制剂在抑制乳腺癌方面具有协同作用.
- 在胰腺癌中观察到PCK1-Cyclin D3相互作用,但不是肝癌,这可能解释了PCK1的各种作用.
结论:
- PCK1在乳腺癌中起着致癌作用,并导致CDK4/6抑制剂耐药性.
- 结合PCK1抑制剂 (everolimus,auranofin) 和CDK4/6抑制剂的联合治疗对乳腺癌治疗有望.
- 这些发现有助于解决PCK1在不同癌症类型中的上下文依赖作用.
相关概念视频
Inhibition of Cdk Activity
6.1K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
M-Cdk Drives Transition Into Mitosis
6.7K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.7K
Combination Therapies and Personalized Medicine
6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Mitogens and the Cell Cycle
8.2K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K


